companies / alchemab-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-16 json
| total_raised | 116,600,000116.6M | ○ |
|---|---|---|
| founded | 2019 | |
| hq | London | |
| industry | unknown | |
| stage | series-a |
Alchemab develops antibody therapeutics by studying immune responses in disease-resistant individuals. It serves patients with hard-to-treat diseases through nature-inspired antibody discovery. Differentiator: adaptive immunity datasets fused with deep learning identify protective antibodies from resilient populations.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-09-01 | series-a | 27,000,00027.0M | null | ○ |
Nginx, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, DoubleClick Floodlight, WordPress, WordPress Block Editor, WP Engine, PHP, MySQL, jquery 3.
| fact | status | src |
|---|---|---|
| Series A, $27.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |